September 22, 2008 by Joe Ponzio

Folks – as you know, I don’t pay lip service to the markets. The Dow dropped and recovered 1,000 points over the past week; and, if you’re looking for that kind of noise, there are plenty of sites out there discussing it. That said, let me paraphrase many investors I…

» Read this article

June 22, 2008 by Joe Ponzio

Today’s research and development (R&D) is tomorrow’s new product or process. The other day we (or more specifically, Phil Fisher) asked, “Does the management have a determination to continue to develop products or processes that will still further increase total sales potentials when the growth potentials of currently attractive product…

» Read this article

June 11, 2008 by Joe Ponzio

In Common Stocks and Uncommon Profits, Phil Fisher outlined fifteen points to look for when analyzing a company for purchase. When valuing a business, our job is to try and predict the future with a degree of accuracy and confidence. If it were as easy as plugging the financials into…

» Read this article

March 5, 2008 by Joe Ponzio

In late July, I posted an analysis of Amylin Pharmaceuticals (AMLN) that was not exactly a favorite of Michael’s. I figured that my response belonged in a post rather than in the comments because it was more of a “noise vs. news” debate, and Michael responded in turn with some…

» Read this article

January 7, 2008 by Joe Ponzio

Welcome to 2008 all. I am going to spend the next day responding to all of the comments from the past two weeks. Let’s get to the heart of the matter: What is going to happen in 2008? It is a question I have been hearing for the past three…

» Read this article

August 24, 2007 by Joe Ponzio

Interestingly enough, quick asked a question that was going to be the topic for today. When does the discounted cash flow model work? When does it not? Is this a method that can be used for all businesses at all times? The short answer is: The discounted cash flow method…

» Read this article

July 27, 2007 by Joe Ponzio

I like to think that I’m doing some good here on the blog. Your emails, comments, and return visits have led me to believe that. That said, I don’t think that I am a “guru” and that everyone else is wrong. My point on this site is simple: you can…

» Read this article

July 26, 2007 by Joe Ponzio

$6.22 billion. That’s what Wall Street is pricing Amylin Pharmaceuticals (AMLN) at these days. If you are a fan of Efficient Market Theory (Buffett isn’t), then you believe that the company is worth that much. You’d also have to believe that the company was fairly valued at $5 back in…

» Read this article